Cellectis under pressure on safety signal in multiple myeloma study

Cellectis (NASDAQ:CLLS) is down 8% after hours after its Phase 1 MELANI-01 trial in multiple myeloma patients was placed on clinical hold by the FDA.

The agency suspended the study after one participant who received candidate UCARTCS1A experienced a fatal heart attack.

Clinical evaluation of the incident is ongoing. The company is working to address the required changes to the MELANI-01 clinical protocol aimed at enhancing patient safety.

UCARTCS1A is an allogeneic, off-the-shelf, gene-edited T-cell product candidate designed for CS1/SLAMF7-expressing blood cancers.

https://seekingalpha.com/news/3588900-cellectis-under-pressure-on-safety-signal-in-multiple-myeloma-study